Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques

American Journal of Health-System Pharmacy

Volumn 63, Issue 18, 2006, Pages 1736-1744

  Harrison, Bruce R ^c   Peters, Byron G ^a   Bing, Michael R ^b  

^a USA   (United States)

^b ST JOHN S MERCY MEDICAL CENTER   (United States)

^c Gateway Medical Research   (United States)

Author keywords

Antineoplastic agents; Compounding; Contamination; Cyclophosphamide; Equipment; Fluorouracil; Pharmacy, institutional, hospital

Indexed keywords

2 PROPANOL; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL;

ARTICLE; BIOLOGICAL SAFETY CABINET; CLOSED SYSTEM DRUG TRANSFER DEVICE; DEVICE; DRUG CONTAMINATION; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; EQUIPMENT; INTERMETHOD COMPARISON; PRIORITY JOURNAL; SURFACE PROPERTY;

EID: 33748768251     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050258     Document Type: Article

References (48)

1. Harrison BR. Safe handling of cytotoxic drugs. In: Perry MC, ed. The chemotherapy source book. 2nd ed. Baltimore: Williams & Wilkins; 1996:905-45.
2. Benedict WF, Baker MS, Haroun L et al. Mutagenicity of cancer chemotherapeutic agents in Salmonella/microsome test. Cancer Res. 1977; 37:2209-13.
3. Matney TS, Nguyen TV, Connor TH et al. Genotoxic classification of anticancer drugs. Teratog Carcinog Mutagen. 1985; 5:319-28.
4. Matheson D, Brusick D, Carrano R. Comparison of the relative mutagenic activity for eight antineoplastic drugs in the Ames Salmonella/microsome and TK± mouse lymphoma assays. Drug Chem Toxicol. 1978; 1:277-304.
5. Schmahl D, Habs M. Experimental carcinogenesis of antitumor drugs. Cancer Treat Rev. 1978; 5:175-84.
6. International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risk to humans. Some antineoplastic and immunosuppressive agents. Vol 26. http://monographs.iarc. fr/ENG/monographs/volume26.pdf (accessed 2006 Jul 17).
7. International Agency for Research on Cancer. Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42 (supplement no. 7). http://monographs.iarc.fr/ENG/monographs/Suppl7.pdf (accessed 2006 Jul 17).
8. Berk PD, Goldberg JD, Silverstein MN et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981; 304:441-7.
9. Kaldor JM, Day NE, Pettersson F et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med. 1990; 322:1-6.
10. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Ped Oncol. 1994; 23:86-98.
11. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. 1985; 78:44-8.
12. Hemminki K, Kyyronen P, Lindbohm M. Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health. 1985; 39:141-7.
13. Selevan SG, Lindbohm M, Hornung RW et al. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med. 1985;313:1173-8.
14. Peelen S, Roeleveld N, Heederik D et al. Toxic effects on reproduction in hospital personnel. The Hague, The Netherlands: Dutch Ministry of Social Affairs and Employment; 1999.
15. Kleinberg ML, Quinn MJ. Airborne drug levels in a laminar-flow hood. Am J Hosp Pharm. 1981; 38:1301-3.
16. Neal AD, Wadden RA, Chiou WL. Exposure of hospital workers to airborne antineoplastic agents. Am J Hosp Pharm. 1983; 40:597-601.
17. McDevitt JJ, Lees PS, McDiarmid MA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med. 1993; 35:57-60.
18. Connor TH, Anderson RW, Sessink PJ et al. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health-Syst Pharm. 1999; 56:1427-32.
19. Burgaz S, Karahalil B, Bayrak P et al. Urinary cyclophosphamide excretion and micronuclei frequencies in peripheral lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics. Mutation Res. 1999; 439:97-104.
20. Brumen V, Horvat D. Work environment influence on cytostatic-induced genotoxicity in oncologic nurses. Am J Ind Med. 1996; 30:67-71.
21. Anderson RW, Puckett WH, Dana WJ et al. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm. 1982; 39:1881-7.
22. Anwar WA, Salama SI, El Serafy MM et al. Chromosomal aberrations and micronucleus frequency in nurses occupationally exposed to cytotoxic drugs. Mutagenesis. 1994; 9:315-7.
23. Evelo CT, Bos RP, Peters JG et al. Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health. 1986; 58:151-5.
24. Sessink PJ, Boer KA, Scheefals AP et al. Occupational exposure to antineoplastic agents at several departments in a hospital: environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health. 1992; 64:105-12.
25. Sessink PJ, Van DeKerkhof MC, Anzion RB et al. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route? Arch Environ Health. 1994; 49:165-9.
26. Pethran A, Schierl R, Hauff K et al. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part 1: monitoring of urinary concentrations. Int Arch Occup Environ Health. 2003; 76:5-10.
27. Wick C, Slawson MH, Jorgenson JA et al. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health-Syst Pharm. 2003;60:2314-20.
28. Sessink PJ, Kroese ED, Van Kranen HJ et al. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health. 1995; 67:317-23.
29. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990; 47:1033-49.
30. Controlling occupational exposure to hazardous drugs. OSHA technical manual (OSHA instruction CPL 2-2.20B CH-4). Chap. 21. Washington, DC: Occupational Safety and Health Administration; 1995.
31. Powell LL, ed. Cancer chemotherapy guidelines and recommendations for practice in cancer care. Pittsburg: Oncology Nursing Society; 1996.
32. Nygren O, Gustavsson B, Ström L et al. Exposure to anti-cancer drugs during preparation and administration. Investigations of an open and a closed system. J Environ Monit. 2002; 4:739-42.
33. Connor TH, Anderson RW, Sessink PJ et al. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health-Syst Pharm. 2002; 59:68-72.
34. Sessink PJ, Rolf ME, Ryden NS. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm. 1999; 34:1311-7.
35. Vandenbroucke J, Robays H. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Pract. 2001; 6:146-52.
36. Tans B, Willems L. Comparative contamination study with cyclophosphamide, fluorouracil, and ifosfamide: standard technique versus a proprietary closed-handling system. J Oncol Pharm Pract. 2004; 10:217-23.
37. Cook TD, Campbell DT. Quasi-experimentation: design & analysis issues for field settings. Boston: Houghton Mifflin; 1979.
38. Sessink PJ, Anzion RB, Van Den Broek PH et al. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci. 1992; 14:16-22.
39. Sessink PJ, Scholtes MM, Anzion RB et al. Determination of cyclophosphamide in urine by gas chromatography-mass spectrometry. J Chromatogr. 1993; 616:333-7.
40. Rubino FM, Floridia L, Pietropaolo AM et al. Measurement of surface contamination by certain antineoplastic drugs using high-performance liquid chromatography: applications in occupational hygiene investigations in hospital environments. Med Lav. 1999; 90:572-83.
41. Martin S, Larson E. Chemotherapy-handling practices of outpatient and office-based oncology nurses. Oncol Nurs Forum. 2003; 30:575-81.
42. National Institute for Occupational Safety and Health. Preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings. NIOSH Publication No. 2004-165. Cincinnati, OH; 2004.
43. Sessink PJ, De Roos JH, Pierik FH et al. Occupational exposure of animal keepers to cyclophosphamide. J Occup Med. 1993; 35:47-52.
44. Sessink PJ, Bos RP. Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf. 1999; 20:347-59.
45. Ku RH. An overview of setting occupational exposure limits (OELs) for pharmaceuticals. Chem Health Saf. 2000; Jan/Feb:34-7.
46. Schulman LJ, Sargent EV, Naumann BD et al. A human health risk assessment of pharmaceuticals in the aquatic environment. Hum Ecol Risk Assess. 2002; 8:657-80.
47. Kiffmeyer TK, Niemöller M, Schirpenbach R et al. Außenkontaminationen von medikamentenverpackungen: vorschlage zum reinigungsverfahen. Krankenhauspharmazie. 2001; 5:207-12.
48. Larson RR, Khazaeli MB, Dillon HK. Monitoring method for surface contamination caused by selected antineoplastic agents. Am J Health-Syst Pharm. 2002; 59:270-7.